Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Typhoid vaccine oral - Prokarium

Drug Profile

Typhoid vaccine oral - Prokarium

Alternative Names: M01ZH09; MICRO-TY; Salmonella typhi oral vaccine - Emergent BioSolutions; Typhella

Latest Information Update: 20 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergent BioSolutions
  • Developer Emergent BioSolutions; Prokarium
  • Class Bacterial vaccines; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Typhoid

Most Recent Events

  • 30 Jan 2009 Emergent BioSolutions completes a phase II trial in Typhoid prevention in USA
  • 09 Jan 2008 Final immunogenicity and adverse events data from a Phase-II trial in Typhoid prevention released by Emergent BioSolutions
  • 11 Oct 2007 Clinical data added to the adverse events and Bacterial Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top